14,265 results on '"Respiratory Syncytial Virus Infections"'
Search Results
2. A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab (JUBILUS)
3. The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
4. RSV Vaccine in Transplant Recipients (RSVax)
5. SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER
6. The Effect of Sevoflurane on Airway Hyperreactivity During the Perioperative Period.
7. Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
8. A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years
9. Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
10. Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
11. Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study (MIViral)
12. Safety and Immunogenicity Study of SCB-1019T in Children
13. A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants
14. Respiratory Syncytial Virus Infection in Exacerbations of Chronic Obstructive Pulmonary Diasease: the RECODE Study (RECODE)
15. Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) (SMART)
16. Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
17. Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
18. A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants
19. A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults
20. RSV Vaccination in Immunocompromised Patients.
21. Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children
22. A Study of EDP-938 in Non-hospitalized Adults with RSV Who Are At High Risk for Complications. (RSVHR)
23. Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older
24. Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
25. A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above
26. Viral Dynamics and Transmission of Influenza, RSV and SARS-CoV-2 in Children
27. A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection
28. MVA-BN-RSV Vaccine Trial
29. A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults (RSV-OA=ADJ-020)
30. Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
31. A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
32. Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older
33. Emission Patterns of Respiratory Syncytial Virus
34. A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
35. A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV
36. A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)
37. Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
38. A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV
39. A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
40. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspension
41. Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
42. Safety and Efficacy of BARS13 in the Elderly
43. Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers
44. Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children
45. A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above
46. A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
47. Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
48. A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus
49. Standardized Phylogenetic Classification of Human Respiratory Syncytial Virus below the Subgroup Level.
50. Irregular seasonality of respiratory syncytial virus infection persists in 2023 in Osaka, Japan
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.